Drug facts
Is compounded tirzepatide the same as Zepbound?
Quick answer
The ingredient guide explains why a compounded vial may contain additives even when both products contain tirzepatide. Only Zepbound and Mounjaro are FDA-approved products with a reviewed label, reviewed manufacturing, and trial data behind them. A compounded preparation is a separate product whose safety, effectiveness and quality FDA does not verify before it is marketed.3
Only two tirzepatide products hold an FDA label12
Eli Lilly makes both brands. Mounjaro is approved to improve blood sugar control in people ages 10 and up with type 2 diabetes, and to reduce major cardiovascular events in adults with type 2 diabetes at high risk for those events. Zepbound is approved for long-term weight management in eligible adults and to treat moderate to severe obstructive sleep apnea in adults with obesity.
That is the fact the rest of this page rests on, and it is why this section of the site exists: when people ask what the label says about compounded tirzepatide, the accurate answer is that there is no such label, and the approved product’s label is the closest thing available.
How far a compounded price sits below the brand depends on the seller. Among the sellers we work with, the Shed review records $299 a calendar month at the starting dose, the Oak review $300 a calendar month at the starting dose and the RxSpan MD review $329 a calendar month. We may earn a commission from these sellers, and the full index orders every seller by price alone.
What is the same1
The active molecule, and therefore the mechanism — tirzepatide acts at both the GIP and GLP-1 receptors. The boxed warning attaches to the molecule, so it applies either way, as do the contraindications. See the boxed warning.
What is different1
On the label — Mounjaro / Zepbound
Approval. Reviewed and approved by FDA for a stated indication.
In a compounded vial
Not FDA-approved. Compounded preparations are not reviewed for safety, effectiveness or quality before they reach a patient.
On the label — Mounjaro / Zepbound
Strength. The label specifies each dose and the concentration of each presentation.
In a compounded vial
Concentration is set by the pharmacy and varies between sellers, which is why a dose in milligrams is a different mark on the syringe from a different vial. See units and milligrams.
On the label — Mounjaro / Zepbound
Dating. An expiration date backed by stability data FDA reviewed.
In a compounded vial
A beyond-use date assigned by the pharmacy, usually much shorter, and varying between pharmacies. See storage and beyond-use dating.
On the label — Mounjaro / Zepbound
Evidence. The label reports randomized trials for the approved product.
In a compounded vial
Evidence varies by preparation. The pivotal tirzepatide trials do not establish the performance of a pharmacy’s compounded formulation.
What that last one really means1
It is not a claim that compounded tirzepatide does not work. The molecule is the same in name. The weight-loss results in SURMOUNT-1 came from the tirzepatide injection used in that study. They do not establish what someone should expect from a specific compounded preparation.
Which is exactly why the pharmacy behind a seller, and what it will tell you about concentration and dating, is worth more attention than the number on its landing page. The evidence, and the usual reasons a vial seems not to work, are on does compounded tirzepatide work?; what a compounded vial is in the first place, and what may be added to it, is on what compounded tirzepatide is. For readers with type 2 diabetes, the diabetes product is compared on compounded tirzepatide vs Mounjaro.
And the price4
The reason anyone weighs this trade-off is cost. What the compounded market actually charges per month — as opposed to what it advertises — is the index.